- Home
- VEON vs RARE Comparison
VEON vs RARE Comparison
Compare VEON & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEON
- RARE
- Stock Information
- Founded
- VEON 1992
- RARE 2010
- Country
- VEON United Arab Emirates
- RARE United States
- Employees
- VEON N/A
- RARE N/A
- Industry
- VEON Telecommunications Equipment
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- VEON Telecommunications
- RARE Health Care
- Exchange
- VEON Nasdaq
- RARE Nasdaq
- Market Cap
- VEON 3.9B
- RARE 3.3B
- IPO Year
- VEON 1996
- RARE 2014
- Fundamental
- Price
- VEON $40.00
- RARE $37.14
- Analyst Decision
- VEON Strong Buy
- RARE Strong Buy
- Analyst Count
- VEON 1
- RARE 15
- Target Price
- VEON $60.00
- RARE $90.53
- AVG Volume (30 Days)
- VEON 276.0K
- RARE 1.1M
- Earning Date
- VEON 08-07-2025
- RARE 07-31-2025
- Dividend Yield
- VEON N/A
- RARE N/A
- EPS Growth
- VEON N/A
- RARE N/A
- EPS
- VEON 6.24
- RARE N/A
- Revenue
- VEON $4,088,000,000.00
- RARE $590,689,000.00
- Revenue This Year
- VEON $5.99
- RARE $18.94
- Revenue Next Year
- VEON $7.19
- RARE $28.93
- P/E Ratio
- VEON $6.42
- RARE N/A
- Revenue Growth
- VEON 8.84
- RARE 33.46
- 52 Week Low
- VEON $25.38
- RARE $29.59
- 52 Week High
- VEON $58.30
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- VEON 34.56
- RARE 52.29
- Support Level
- VEON $34.55
- RARE $36.01
- Resistance Level
- VEON $41.66
- RARE $40.19
- Average True Range (ATR)
- VEON 2.87
- RARE 1.47
- MACD
- VEON -1.39
- RARE 0.06
- Stochastic Oscillator
- VEON 27.61
- RARE 49.92
About VEON VEON Ltd. ADS
VEON Ltd is a United Arab Emirates-based digital operator providing connectivity and Internet services to corporations and individuals. The company offers mobile and fixed-line telecommunications services through a range of traditional and broadband mobile technologies. The company's reportable segments consist of the following five segments: Pakistan, Ukraine, Kazakhstan, Bangladesh, and Uzbekistan. It provides its services under the Beeline, Kyivstar, Banglalink, and Jazz brands. It generates the majority of its revenue from Pakistan.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.